Industry Snapshots:

• The market size of the worldwide Drug Delivery Devices Industry will surpass US$ 464.83 billion in 2025, and by 2035, it is projected to reach US$ 954.47 billion, growing at a CAGR of 7.4% during the forecast period.

• The drug-delivery devices market comprises tools that administer medicines such as injectors, pumps, inhalers, transdermal patches, and implantable systems across hospitals, clinics, and home care setups. WHO reported that noncommunicable diseases are responsible for approx. 41 million deaths each year (i.e. 74% of overall global deaths) between the ages of 30 to 69 years. A growing trend of outpatient and self-care is boosting the acceptance of easy-to-use and connected devices that support remote monitoring. Regulatory authorities such as FDA, are expanding the approvals of the drug device combination which encourages innovation and need in the market. The success of Manufacturers relies on their ability to provide safe, user friendly and affordable products that meet clinical demands and ensure accessibility to each individual of the rural and urban areas.

• In November 2024, Sandoz opened a new device development center in Cambridge, UK, which will act as a global hub for creating advanced drug delivery devices to support its pipeline of affordable medicines.

Growth Catalysts:

• Growing chronic illness prevalence and expanding demands for self-administration at home: The rising incidence of incurable diseases such as cardiovascular, respiratory, and CNS disorders is propelling the demand for drug delivery devices. The WHO states that, in 2025, cardiovascular diseases cause 19.8 million deaths annually, indicating about 32% of deaths. It highlights the need for drug delivery devices as safe, accurate, and user-friendly delivery systems which fuels the adoption of self-administration and home-based treatments, enabling patients to manage therapies effectively outside hospital settings. The increasing expenditure on home healthcare further reflects the shift toward personalized and convenient care. Advanced injectors, wearable pumps, and inhalation systems are gaining traction as they enhance treatment adherence, improve patient comfort, and reduce dependency on clinical facilities—particularly for the management of chronic illnesses.

• Rising demand for biological and biosimilar drugs: The transition of the healthcare sectors is driven by the growing adoption of biologic therapies and their biosimilar counterparts which are fueling the market expansion. The demand for advanced drug delivery systems such as auto-injectors, pre-filled syringes, and wearable infusion devices biosimilars replicating complex biologic therapies that are primarily injectable or infusible is escalated by the growing proportion of the approvals by the regulatory authorities of several drug delivery devices. The National Center for Biotechnology Information reported that, the European Medicines Agency had approved 101 biosimilars, while the U.S. FDA had approved 53 biosimilars in May 2024. This robust expansion of biosimilar approvals is accelerating innovation and adoption in the drug delivery devices market. As biologics require precision, stability, and patient convenience, manufacturers are increasingly focusing on user-friendly, self-administrable delivery devices.

Industry Innovations:

• Computerized and advanced drug delivery systems: The drug delivery devices industry witnessed a major technological advancement with the introduction of smart and interconnected drug delivery systems. These devices combine wireless communication technology, sensors, and data analytics to provide accurate, real-time monitoring of patient adherence and dosage patterns. Using connectivity to cloud-based systems which allows the medical professionals to monitor patient progress from a distance and maximize treatment results. Wearable injectors with Bluetooth or NFC technology along with smart insulin pens, and inhalers represents the latest advancements in this emerging field. Growing demand for value-based and individualized care, along with the increasing acceptance of digital health ecosystems, is propelling the development of connected drug delivery solutions. 

• Transdermal drug delivery devices: The major innovations in drug delivery devices, such as microneedles and transdermal medication delivery technology which, provide a less intrusive option to conventional injections. This method minimizes discomfort and anxiety while improving drug absorption and accuracy through the use of micro-scale needles. The safety and effectiveness of drug delivery devices are enhanced by advancements in materials and microfabrication and disposal issues are being addressed by biodegradable alternatives. Increased R&D spending, regulatory backing, and the need for painless delivery are driving market expansion and establishing these systems as a crucial part of smart wearable technology and medication delivery in the future.

Potential Opportunities 

• Development in home-based drug delivery devices and self-administration: The global market for drug delivery devices has a significant opportunity owing to the rising need for self-administration in home healthcare facilities. Prefilled syringes and auto-injectors are examples of sophisticated delivery systems that are more prevalent ascribed to the increased prevalence of chronic illnesses, including diabetes and asthma. It is easy to administer the medications safely outside of clinical setups, which reduces the need for hospitalization and treatment expenses. Self-injectable systems are becoming more readily accessible, attributed to design and usability advancements. The demand for portable medicine delivery systems has increased due to the global movement toward decentralized healthcare, particularly in emerging economies and among older populations.

• Adoption of 3D Printing in Device Manufacturing: The embracement of 3D printing technology will create significant opportunities in the drug delivery devices market by enabling rapid, precise, and cost-effective production of complex, patient-specific systems such as microneedle patches and implantable reservoirs. In the coming years, innovations like PinPrint’s 3D-printed microneedle patch, developed using its advanced “iCLIP” process, will transform the delivery of vaccines and therapeutic agents through painless, needle-free intradermal application. This technology can enhance dosing accuracy, patient comfort, and self-administration capabilities. The rising requirement for biologics and personalized therapies continue, 3D printing will drive faster prototyping, sustainable production, and localized manufacturing, positioning it as a key enabler of innovation and growth in the future drug delivery devices market.

Recent Industry Updates:

• October 2025: GE HealthCare designed Carestation 850 to help clinicians more confidently care for each patient and optimize procedural outcomes. It features an intuitive widescreen display and an enhanced user interface to deliver clear data visualization.

• September 2025:  ARS Pharmaceuticals, Inc. announced that the Japanese Pharmaceuticals and Medical Devices Agency has approved neffy® (epinephrine nasal spray) in 1 mg and 2 mg doses for treating anaphylactic allergic reactions in adults and children over 15 kilograms.

• September 2025: Apiject Systems Corp. submitted the New Drug Application for regulatory approval of the Glycopyrrolate in the Apiject injection device to the Food and Drug Administration (FDA).

Industry Outlook Scope:

By Device Type

• Injection Devices

• Transdermal Patches

• Inhalers

• Implants

• Infusion Pumps

• Nebulizers

• Ocular Delivery Systems

• Topical Delivery System

By Route of Administration

• Injectables

• Ocular

• Oral

• Transdermal

• Nasal

• Inhalational

By Mode of Operation

• Manual/Mechanical

• Automated/Smart

• Semi-automated

By Application 

• Cardiovascular Diseases

• Cancer

• Central Nervous System Disorders

• Diabetes

• Autoimmune Diseases

• Respiratory Diseases

• Infectious Disease

By Usage Type

• Single Use

• Multi-Use

By End-User

• Hospitals

• Ambulatory Surgical Centers

• Homecare Settings

• Diagnostics Centres & Specialty Clinics

Category Insights:

By Device Type

• Inhalers hold the largest market share: The inhalers segment holds the largest market share in the drug delivery devices market due to the growing prevalence of respiratory conditions, such as asthma and COPD. It enhances the compliance of the patient with satisfaction. New developments, legal clearances, and environmentally friendly designs increase treatment alternatives and support sustainability objectives. The trend toward home care and self-administration leads to segment dominance.

• Injection devices exhibit the fastest growth: The injection devices segment is witnessing rapid growth, due to the increasing use of biologics and biosimilars, which need injectable administration to be effective, a growing desire for self-administration and home-based care, as well as ongoing technology improvements such as smart and connected injectors., advances like wearable and microneedle injectors, regulatory approvals for subcutaneous formulations, and rising rates of chronic disease are improving patient convenience and adherence, making injection devices the most innovative and dynamic market segment.

By Applications

• Diabetes leads the market: The diabetes segment dominates the drug delivery device market owing to the increasing prevalence of diabetes globally and the continuous need for insulin treatment, which drives consistent device demand. Ongoing developments in smart insulin pens, pumps, and linked delivery systems, along with an increasing tendency toward self-administration and home-based care, further solidify its segment growth. The upsurge of regulatory approvals for innovative delivery systems fuels the segment expansion.

• Central Nervous System disorders see rapid adoption: The central nervous system disorders segment is growing rapidly due to the growing incidence of neurological conditions like epilepsy, Parkinson's, and Alzheimer's. The growing use of gene and biologic therapies, together with advancements in long-acting and controlled-release devices, is improving patient outcomes and treatment precision, which is driving this segment's rapid expansion.

Regional Dynamics:

• North America holds the highest market share: The North America region holds the highest market share in the drug delivery devices market. North America dominates the global market for drug delivery devices due to several factors, including a high prevalence of chronic diseases, about 38 million Americans having diabetes, excessive health care spending on chronic care, and a quick uptake of cutting-edge delivery procedures (insulin pumps, computerized insulin delivery, smart pens, and connected injectors). The 2025 FDA approvals and Breakthrough Device designations are driving growth in the North American drug delivery device market, accelerating innovation, adoption, and reaching 1,176 designations, demonstrating sustained innovation and approval momentum.

• Asia Pacific exhibits fastest growth: The Asia Pacific region is witnessing the fastest growth in the drug delivery devices market, ascribed to the rising incidence of chronic conditions, the development of healthcare infrastructure, and robust government backing for domestic production and regulatory approvals. Utilizing programs like India's medical device parks program and the NMPA's 2025 device standards revision plan, nations like China and India are speeding up the development of new devices. Moreover, the region is moving toward sophisticated, patient-friendly delivery systems, witnessed by the fact that in 2024, 53%of approved medications received autoinjector formulations within five years of original authorization in Japan, which facilitates the market expansion in the Asia Pacific.

Industry Competition:

• Abbott

• Becton, Dickinson and Company

• Boston Scientific Corporation

• Gerresheimer AG

• Medtronic

• Novartis AG

• Stryker

• Teleflex Incorporated

• Terumo Medical Corporation

• W. L. Gore & Associates, Inc. 

What to Expect from Outlook:

1. Save time carrying out entry-level research by identifying the size, growth trends, major segments, and leading companies in the Global Drug Delivery Devices Market.

2. Use PORTER’s Five Forces analysis to assess the competitive intensity and overall attractiveness of the Global Drug Delivery Devices Market.

3. Profiles of leading companies provide insights into key players’ regional operations, strategies, financial results, and recent initiatives.

4. Add weight to presentations and pitches by understanding the future growth prospects of the Global Drug Delivery Devices Market with a forecast for the decade by both market share (%) & revenue (USD Billion).